Sarah Nikiforow, Ph.D.
Affiliations: | 2004 | Yale University, New Haven, CT |
Area:
ImmunologyGoogle:
"Sarah Nikiforow"Parents
Sign in to add mentor| Kim Bottomly | grad student | 2004 | Yale | |
| (The role of CD4+ T cells in preventing Epstein -Barr virus -induced B cell proliferation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Frigault MJ, Graham CE, Berger TR, et al. (2024) Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood |
| Shapiro RM, Kim HT, Dulery R, et al. (2024) Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival. Blood Advances |
| Nikiforow S, Whangbo JS, Reshef R, et al. (2024) Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances |
| Schreiber B, Tripathi S, Nikiforow S, et al. (2024) Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review. Seminars in Nephrology. 151498 |
| Hammond TC, Purbhoo MA, Kadel S, et al. (2024) A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nature Communications. 15: 974 |
| Mahadeo KM, Baiocchi R, Beitinjaneh A, et al. (2024) Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet. Oncology |
| Garcia JS, Kim HT, Murdock HM, et al. (2024) Prophylactic maintenance with venetoclax/azacitidine after reduced intensity conditioning allo-transplant for high risk MDS and AML. Blood Advances |
| Little JS, Duléry R, Shapiro RM, et al. (2023) Opportunistic Infections in Patients Receiving Post-Transplant Cyclophosphamide: Impact of Haploidentical Versus Unrelated Donor Allograft. Transplantation and Cellular Therapy |
| Shapiro RM, Kim HT, Ansuinelli M, et al. (2023) Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Advances |
| Maurer K, Ho VT, Inyang E, et al. (2023) Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Advances |